Localized Mucosa-Associated Lymphoid Tissue Lymphoma Treated With Radiation Therapy Has Excellent Clinical Outcome

Tsang, Richard W.; Gospodarowicz, Mary K.; Pintilie, Melania; Wells, Woodrow; Hodgson, David C.; Sun, Alexander; Crump, Michael; Patterson, Bruce

doi:10.1200/jco.2003.06.085

Cited by 352 publications

(223 citation statements)

References 53 publications

Supporting

Mentioning

206

Contrasting

Unclassified

Order By: Relevance

“…Radiotherapy alone with a total dose of 30-35 Gy in 15-20 fractions (3-4 weeks) has been showed to guarantee a low failure-free rate in MALT lymphomas. 26 However, in patients with primary pulmonary lymphomas of MALT type the results were not as good as in the whole population of MALT lymphomas; this may be explained by the fact that lungs are mobile organs. 26 Chemotherapy with anthracyclines or combined modality therapy mainly with a CHOP regimen, was associated with a 10-year lymphoma specific survival of 72% in a study on 50 patients.…”

Section: Primary Lung Lymphomasmentioning

confidence: 77%

“…26 However, in patients with primary pulmonary lymphomas of MALT type the results were not as good as in the whole population of MALT lymphomas; this may be explained by the fact that lungs are mobile organs. 26 Chemotherapy with anthracyclines or combined modality therapy mainly with a CHOP regimen, was associated with a 10-year lymphoma specific survival of 72% in a study on 50 patients. 21 In this study no differences in survival were seen between subjects with low grade MALT lymphoma and patients in which MALT lymphoma was associated to areas of large B-cell lymphoma.…”

Section: Primary Lung Lymphomasmentioning

confidence: 77%

“…[14][15][16][17][18][19][20][21][22][23][24][25] Two outcome studies, 26 20 In patients with MALT type lymphoma the overall survival at one year was 91%, the overall survival at five years was 68% and the overall survival at ten years was 53%. These data were weighted taking into account the fact that this lymphoma is an indolent disease usually with a long natural course, and that it is a multifocal disease in which a radical resection is not easy to perform.…”

Section: Primary Lung Lymphomasmentioning

confidence: 99%

See 2 more Smart Citations

Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation

Zinzani¹,

Martelli²,

Poletti³

et al. 2008

Haematologica

View full text Add to dashboard Cite

Extranodal non-Hodgkin's lymphomas constitute 20-25% of overall non-Hodgkin's lymphomas cases and can be managed with very different therapeutic strategies. Therefore, the Italian Society of Hematology and the two affiliate societies (the Italian Society of Experimental Hematology and the Italian Group of Bone Marrow Transplantation) appointed a panel of experts to produce clinical practice-guidelines for the management of these conditions. Primary lung and mediastinal lymphomas were the objective of this part of the project. The panel of experts produced the following key recommendations that were graded according to the strength of evidence and clinical judgement. The first-line therapy for non-MALT primary lung non-Hodgkin's lymphomas should include anthracycline-based chemotherapy with CHOP or CHOP-like, MACOP-B or MACOP-B-like regimens (grade D). Rituximab association with chemotherapy needs to be evaluated within approved clinical trials. Second-line therapy with high-dose chemotherapy and autologous stem cell transplantation is recommended (grade B). In patients with MALT primary lung non-Hodgkin's lymphomas, the recommended first-line therapy should include chlorambucil, CHOP, CHOP-like or fludarabine-containing regimens (grade B). Radiotherapy is to be reserved for patients with a unique, small lesion in a poorly mobile site and with contraindication to surgery (grade D). Rituximab should be administered only within approved clinical trials. For treatment of primary mediastinal large B-cell lymphomas, the recommended first-line therapy is a chemotherapy and radiotherapy association (grade B). An anthracycline-based chemotherapy with CHOP, MACOP-B or VACOP-B is recommended (grade B). Rituximab combination with chemotherapy is highly suggested but only for patients enrolled into approved clinical trials. Patients with an inadequate early response should be candidates for early intensification with high-dose chemotherapy (grade C). Patients with refractory or relapsed disease should undergo rescue programs including intensive, non-cross-resistant debulking treatment followed, in chemosensitive patients, by high-dose chemotherapy and autologous stem cell transplantation (grade B).

show abstract

Section: Primary Lung Lymphomasmentioning

confidence: 77%

Section: Primary Lung Lymphomasmentioning

confidence: 77%

Section: Primary Lung Lymphomasmentioning

confidence: 99%

See 1 more Smart Citation

Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation

Zinzani¹,

Martelli²,

Poletti³

et al. 2008

Haematologica

View full text Add to dashboard Cite

show abstract

“…Localized thyroid MALT lymphoma can be treated with surgical resection with 100% survival at 5 years [5,8–10]. Review of 103 cases done by Tsang et al with localized (stage IE/IIE) extra nodal MALT lymphoma had overall 5 years survival of 98% in 85 patients with extra nodal MALT lymphoma treated with radiation therapy alone [11]. The optimal treatment regimen and follow-up for these patients remains controversial.…”

Section: Discussionmentioning

confidence: 99%

Primary thyroid MALToma– a rare diagnosis of an unassuming thyroid nodule

Shrestha

Aderhold

Swierczynski

et al. 2018

Journal of Community Hospital Internal Medicine Perspectives

View full text Add to dashboard Cite

Primary thyroid lymphoma, although a rare malignancy, can arise in common chronic inflammatory conditions such as Hashimoto’s thyroiditis. Incidental finding of a thyroid nodule with chronic thyroid inflammation warrants further investigation. Early detection of malignancy can play a vital role in improved outcomes. We report a case of a 60-year-old male who presented to the clinic for a routine visit. An enlarged, firm, non-tender thyroid gland was appreciated on exam with high thyroid stimulating hormone (TSH) level. Fine needle aspiration of the mass revealed nonspecific atypical lymphocytes. The pathology and immunohistochemical stains were consistent with histologic impression of extra nodal marginal B-cell lymphoma (mucosa-associated lymphoid tissue [MALT] lymphoma) and Hashimoto’s thyroiditis. Patient was treated with thyroxine after complete surgical excision of left thyroid lobe and remains in remission with close follow-up with his primary care provider. Primary thyroid MALT lymphoma follows an indolent process and remains asymptomatic in most patients. These are usually found to arise at sites of ongoing chronic inflammation with underlying autoimmune or infectious etiologies. Treatment modalities include surgical excision and/or radiation therapy for localized lesions, with both radiation and chemotherapy indicated for disseminated disease.

show abstract

“…MALT lymphoma is generally of low grade and indolent growth while DLBCL is high grade with aggressive growth. The mixed variant behaves more similarly to DLBCL than MALT [33,35,42,44,45]. Staging of PTL is based on extension from the thyroid gland.…”

Section: Primary Thyroid Lymphomamentioning

confidence: 99%